Harvest Investment Advisors LLC Takes Position in Amgen Inc. $AMGN

Harvest Investment Advisors LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 6,693 shares of the medical research company’s stock, valued at approximately $2,191,000. Amgen accounts for 1.2% of Harvest Investment Advisors LLC’s holdings, making the stock its 22nd biggest holding.

A number of other institutional investors also recently modified their holdings of AMGN. Robeco Institutional Asset Management B.V. boosted its stake in shares of Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after purchasing an additional 43,884 shares in the last quarter. Curtis Advisory Group LLC acquired a new position in Amgen during the 4th quarter worth about $1,669,000. Adell Harriman & Carpenter Inc. lifted its position in Amgen by 7.9% during the 4th quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after buying an additional 1,609 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in Amgen during the 4th quarter worth about $22,441,000. Finally, Sigma Planning Corp lifted its position in Amgen by 24.0% during the 4th quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company’s stock worth $5,889,000 after buying an additional 3,488 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.85% of the stock is currently owned by corporate insiders.

Amgen Trading Down 0.8%

Shares of Amgen stock opened at $347.84 on Wednesday. The business has a fifty day simple moving average of $341.02 and a two-hundred day simple moving average of $345.89. Amgen Inc. has a 1 year low of $267.83 and a 1 year high of $391.29. The company has a market capitalization of $187.73 billion, a price-to-earnings ratio of 24.21, a P/E/G ratio of 3.52 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter last year, the firm earned $4.90 earnings per share. The company’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts forecast that Amgen Inc. will post 22.38 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on AMGN. Guggenheim reduced their price target on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a research report on Monday, May 4th. Barclays initiated coverage on Amgen in a research note on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price target for the company. Daiwa Securities Group lowered their price target on Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. Canaccord Genuity Group started coverage on shares of Amgen in a report on Monday, April 20th. They set a “hold” rating and a $366.00 target price on the stock. Finally, Argus dropped their target price on shares of Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a report on Wednesday, May 20th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $354.42.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.